Adis R&D Insight™

Vendor UpdateSLA P&HT Division Meeting

April 8, 2008

• Total number of RDI drug profiles = 23,296Total number of RDI drug profiles = 23,296• Number of new profiles added per month = 80Number of new profiles added per month = 80• Number of significant updates per month = 992Number of significant updates per month = 992• Active drug profiles = 43.1% of the total database.Active drug profiles = 43.1% of the total database.• Inactive/discontinued drug profiles = 56.9% of database.Inactive/discontinued drug profiles = 56.9% of database.• Number of profiles with chemical structures = 8952Number of profiles with chemical structures = 8952• Number of companies covered = 3589Number of companies covered = 3589• Number of company profiles linked = 406 Number of company profiles linked = 406 • Number of companies tracked by Lehman Bros = 80-100Number of companies tracked by Lehman Bros = 80-100• Number of profiles with a Lehman table = 995Number of profiles with a Lehman table = 995• Therapeutic Area Coverage = ALL plus Diagnostic Therapeutic Area Coverage = ALL plus Diagnostic

agents, Cell therapies, Gene therapies and Vaccines.agents, Cell therapies, Gene therapies and Vaccines.• Number of Indications = 1283Number of Indications = 1283

*February 2008*February 2008

• Total number of RDI drug profiles = 23,296Total number of RDI drug profiles = 23,296• Number of new profiles added per month = 80Number of new profiles added per month = 80• Number of significant updates per month = 992Number of significant updates per month = 992• Active drug profiles = 43.1% of the total database.Active drug profiles = 43.1% of the total database.• Inactive/discontinued drug profiles = 56.9% of database.Inactive/discontinued drug profiles = 56.9% of database.• Number of profiles with chemical structures = 8952Number of profiles with chemical structures = 8952• Number of companies covered = 3589Number of companies covered = 3589• Number of company profiles linked = 406 Number of company profiles linked = 406 • Number of companies tracked by Lehman Bros = 80-100Number of companies tracked by Lehman Bros = 80-100• Number of profiles with a Lehman table = 995Number of profiles with a Lehman table = 995• Therapeutic Area Coverage = ALL plus Diagnostic Therapeutic Area Coverage = ALL plus Diagnostic

agents, Cell therapies, Gene therapies and Vaccines.agents, Cell therapies, Gene therapies and Vaccines.• Number of Indications = 1283Number of Indications = 1283

*February 2008*February 2008

Adis R&D Insight - StatisticsAdis R&D Insight - Statistics

Adis R&D Insight: Sources

• Detailed drug profiles derived from the following sources– Company contacts– Press releases– International conferences– Company websites– More than 1,300 biomedical / medical journals

• Detailed drug profiles derived from the following sources– Company contacts– Press releases– International conferences– Company websites– More than 1,300 biomedical / medical journals

Adis R&D Insight NEW! For 2007/2008

• Upgraded search functionality• Improved ease of use• Links to original sources• Major improvements to customizing

preferences and push alerting

BROWSE function

Separate lists for Biological and Chemical classes

List View/Tree View option

Allows searching on synonyms

Upgraded Search FunctionalityBiological and Chemical Class

Route and Formulation

New tab allows search by

• Route of administration

• Formulation

Upgraded Search Functionality

Upgraded Search Functionality

Organization Renamed parameter for better classification of drug developers Search by Organization Type or Ownership Type

Phase

‘Highest Phase’ and ‘Phase is’ New ‘Phase filter’ option Updated and expanded Phase list

Upgraded Search Functionality

Country Hierarchy

• Country searching is expanded to provide the ability to confidently and simply search by broad geographical / political region.

• Addition of ‘Tree View’

Upgraded Search Functionality

Fast Track

• Allows to search compounds that were assigned Fast Track status by the FDA in the US

Upgraded Search Functionality

‘Orphan Drug’

Orphan Drug designation for a particular indication

Orphan designation country

‘Any Indication or Country’: search ALL profiles were Orphan Drug exists

Upgraded Search Functionality

Full Text

‘Full Text’ has replaced the ‘Text Contains’ free text searching option.

Can be partnered with a Category, which will search a specific part of the profile.

Search term will be highlighted in yellow when you open the profile

Upgraded Search Functionality

Addition of Disease Qualifiersa qualifier may be added to an indicationa qualifier comment can be added to provide additional information

Improved Ease of Use

More Tabular Content

Route listed in Phase of Development Table

Orphan Designation

Brand Name Table

Improved Ease of Use

Links to Original Sources

Journal FullText option in recordsOpen access linking capability to link

to your journal holdings

Results Page

Choose Columns for viewing on Results Page

Customization

Development table

Filtering by search

Sorting by heading

Customization

New ALERTS features:

Multiple email addresses can be set up for a single email alert

Searches from both R&D Insight and Clinical Trials Insight can be included in a single alert

Users will be able to export, print, chart results from their Alerts

Run search from last alert

Alerts

Customer Engagement Activities- 2007Customer Engagement Activities- 2007

• Online Surveys conducted• Key Takeaways

– Areas of expanding importance are drug targets and new formulations

– Greater need for financial data, patent, and licensing/deals opportunities

– Improved ability in accessing specific data points

– Timeliness and comprehensiveness is critical

• Online Surveys conducted• Key Takeaways

– Areas of expanding importance are drug targets and new formulations

– Greater need for financial data, patent, and licensing/deals opportunities

– Improved ability in accessing specific data points

– Timeliness and comprehensiveness is critical

Next Steps for Adis R&D InsightNext Steps for Adis R&D Insight

• Customer roundtables to determine and continue to drive specific major enhancements– US and Europe during the weeks

of March 31st and April 4th – Representation from all user and

customer types• Improve comprehensiveness of

coverage through the content acquisition initiative (technology and process review)

• Customer roundtables to determine and continue to drive specific major enhancements– US and Europe during the weeks

of March 31st and April 4th – Representation from all user and

customer types• Improve comprehensiveness of

coverage through the content acquisition initiative (technology and process review)

Feedback and Comments

Adis Business IntelligenceClient Services

clientsupport@wolterskluwer.com1-877-872-2347 option 1